Zydus Lifesciences rose 1.13% to Rs 353 after the company said its board will consider a share buyback on 20 May 2022.
The board will also consider FY22 results and final dividend on 20 May 2022.Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
On a consolidated basis, the company's net profit fell 5.08% to Rs 500.40 crore on 0.61% increase in revenue from operations to Rs 3,655 crore in Q3 FY22 over Q3 FY21.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
